Cite
HARVARD Citation
Hiraoka, A. et al. (2022). Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis. Hepatology research. 52 (3), pp. 308-316. [Online].